Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Affimed Ord Shs (NQ: AFMD )

5.550 +0.450 (+8.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 216,256
Open 5.120
Bid (Size) 5.450 (2)
Ask (Size) 5.900 (1)
Prev. Close 5.100
Today's Range 5.100 - 5.570
52wk Range 2.235 - 8.950
Shares Outstanding 15,227,463
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q1 2024
AFMD stock results show that Affimed beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Affimed Reports First Quarter 2024 Financial Results & Business Update
From Affimed N.V.
Via GlobeNewswire

Performance

YTD
-11.20%
-11.20%
1 Month
-17.66%
-17.66%
3 Month
+3.35%
+3.35%
6 Month
-10.12%
-10.12%
1 Year
-11.20%
-11.20%

More News

Read More
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
From Affimed N.V.
Via GlobeNewswire
Why Is German Biotech Affimed Stock Soaring On Monday?
Via Benzinga
Why Affimed Shares Are Soaring
Via Benzinga
A Preview Of Affimed's Earnings
Via Benzinga
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
From Affimed N.V.
Via GlobeNewswire
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Annual General Meeting of Shareholders
From Affimed N.V.
Via GlobeNewswire
7 Penny Biotech Stocks to Triple Your Investment
Via InvestorPlace
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
From Affimed N.V.
Via GlobeNewswire
Small-Cap Sensations: 3 Stocks Under $10 With 10X Potential
Via InvestorPlace
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
From Affimed N.V.
Via GlobeNewswire
AFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Affimed Reports 2023 Financial Results and Operational Progress
From Affimed N.V.
Via GlobeNewswire
Earnings Scheduled For March 28, 2024
Via Benzinga
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
From Affimed N.V.
Via GlobeNewswire
ASTR Stock Alert: Astra Space Is Going Private
Via InvestorPlace
Why Is AerSale (ASLE) Stock Down 18% Today?
Via InvestorPlace
Why Is Affimed (AFMD) Stock Moving Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
7 of the Best Speculative Stocks You Can Snag for Less Than $1
Via InvestorPlace
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.